MAPT and Alzheimer disease: Aβ oligomers in AD directly interfere with N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isooxazole-propionic acid (AMPA) receptor signaling, impair long-term potentiation, and reduce dendritic spine density, while tau pathology disrupts axonal transport and synaptic vesicle cycling [65,66].